Tyrosine Kinase Inhibitor Active in Heavily Treated Renal Cell Carcinoma
NASHVILLE, Tenn. -- An investigational multitargeted drug produced objective responses in clear-cell renal cell carcinoma (ccRCC), irrespective of prior exposure ...
Read moreDetails
